LiliumX, an innovative BioTech start-up focused on the development of next-generation antibody-based therapeutics, has unveiled its new brand name, and welcomed three top industry leaders to the business, after securing US$7.8 million in investment.
Established in 2021 by Co-founders Arne Scheu and Irsyad Khairil, following their research into ‘LEGO’ protein technologies when studying at the University of Oxford, LiliumX was initially founded to develop a rapid modular platform that enables the fast and efficient construction of better antibody-based drugs, such as bispecific antibody-drug conjugates (bispecific ADCs).
Dr Arne Scheu, Co-founder and CEO of Valink Therapeutics, said: “Valink Therapeutics started with a vision to find truly novel drugs, combining features to build and screen drug candidates that could treat cancer in synergistic and even unexpected ways. We are now excited to release a modular platform that seamlessly combines multivalency, multispecificity, and drug conjugation, while rebranding as Valink Therapeutics to signify the extension beyond bispecificity alone, by Valency and Linking of small molecules into antibody-drug conjugates. We are delighted to enter this next stage of development with the support of our investors, Innovate UK, and new appointments Alex Lugovskoy (NED) and Jose Munoz-Olaya (CSO).”
Click below to share this article